Chardan Capital Maintains Buy on Prothena Corp, Maintains $18 Price Target
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Chardan Capital analyst Rudy Li maintains Prothena Corp (NASDAQ:PRTA) with a Buy and maintains $18 price target.
Chardan Capital analyst Rudy Li maintains Prothena Corp (NASDAQ:PRTA) with a Buy and maintains $18 price target.